Research peptide compliance in Australia rests on one principle: the label does not decide the legal status of a product, its use and promotion do. A vial marked "research use only" is still a therapeutic good in the eyes of the regulator if it is marketed or used to modify a physiological process. This guide sets out what the Therapeutic Goods Administration (TGA) says, what that means for laboratories and institutions, and which records a buyer should hold.
This is general information, not legal advice. For a specific peptide, import or study, confirm the position with the TGA, your institution's research office or a lawyer experienced in therapeutic goods law.
TL;DR
- "Research use only" or "not for human use" wording does not change a product's regulatory status under TGA rules.
- Peptides promoted or used to treat or modify physiological processes generally need ARTG registration before supply or advertising, unless an exemption applies.
- Any use in people, including a trial, needs TGA notification or approval plus Human Research Ethics Committee (HREC) oversight.
- Imports can be intercepted by the Australian Border Force, with loss of goods and money.
- Compliance documents to keep: Certificate of Analysis (CoA), batch number, HPLC and mass spec data, supplier details, import records, ethics approvals.
Table of Contents
- What the TGA regards as a therapeutic peptide product
- Why "research use only" does not settle compliance
- Compliance map by type of user
- Laboratory use: scheduling, possession and import
- Human research: CTN, CTA and ethics oversight
- Prescribers and the clinical pathway
- Supplier due diligence: what to verify
- An internal compliance file, step by step
- Our perspective
- Ordering for laboratory use
- FAQ
- Sources
What the TGA regards as a therapeutic peptide product
The TGA regulates therapeutic goods: medicines, medical devices and similar products. Its guidance on therapeutic peptide products covers importing, supplying, manufacturing and advertising.
The test is purpose, not chemistry. A peptide promoted or used to prevent, cure or alleviate a disease, or to modify a physiological process, must be registered in the Australian Register of Therapeutic Goods (ARTG) before it is supplied or advertised, unless a specific exemption applies. Registration is the market authorisation process through which the TGA assesses safety, quality and effectiveness.
Two consequences follow:
- A peptide used as an in-vitro reagent, for assay work or analytical standards, sits differently from one marketed for body composition, recovery or weight loss.
- Marketing language counts. Claims about fat loss, healing or performance on a product page can bring a product into therapeutic goods territory.
Why "research use only" does not settle compliance
The TGA states that wording such as "research use only" or "not for human use" does not alter regulatory status. Australia's health leaders have gone further. The Department of Health, Disability and Ageing has warned about growing availability, promotion and use of unapproved peptide products, and has described "research use only" labelling as a tactic some suppliers use to mislead consumers and avoid scrutiny.
That statement is aimed at consumer-directed supply. It sets the standard any research supplier is judged against: documented identity and purity, a genuine laboratory customer base, no therapeutic claims, and no encouragement of human use.
Health warnings behind the enforcement focus
As of June 2026, the same department notice reports that hospitalisation data from Australian states and territories links unapproved peptides, including BPC-157, GHK-Cu, TB-500 and CJC-1295, to serious harms such as liver damage and severe allergic reactions.
Counterfeits add a separate risk. The TGA detected fake semaglutide illegally imported into Australia, and the WHO issued a medical product alert on falsified Ozempic) covering batches found in Brazil, the UK and the US. Unverified identity is a compliance problem and a safety problem.
Compliance map by type of user
| User | Main obligation | Key documents |
|---|---|---|
| Laboratory (in-vitro, analytical) | Use strictly non-human; confirm import and scheduling status of each compound | CoA, batch records, import records, internal use log |
| Institution or university | Ethics and biosafety review; procurement controls | HREC records, supplier qualification file |
| Sponsor of a human trial | TGA CTN or CTA, plus HREC approval | Trial notification, protocol, product quality data |
| Prescriber | Use established access pathways for unapproved goods | Prescriber authority documents, patient records |
| Individual consumer | Peptides for personal use are not a research channel | Not applicable |
The last row matters. Research-grade material is not a route to personal use, and this site does not present it as one.
Laboratory use: scheduling, possession and import
Three separate rule sets can apply to one vial.
- Therapeutic goods rules. Govern advertising, supply and manufacture, and registration in the ARTG.
- Poisons Standard scheduling. Some peptides are listed in schedules that restrict supply or possession. As one example, a TGA delegate's interim decision in 2024 proposed a new Schedule 4 entry and an Appendix D entry for BPC-157, in response to 48 import referrals since 1 July 2022. Check the current Poisons Standard for the status of every compound you order, because entries change.
- Customs and border rules. The TGA coordinates with the Australian Border Force to intercept unlawful imports of unapproved peptide products, which can end in total loss of the goods and the purchaser's money.
Before ordering, check each compound against the current Poisons Standard and TGA peptide pages, and record the result. Our guides on documents Australian labs attach to import research peptides and on HS codes for peptides cover the paperwork side of customs clearance.
Human research: CTN, CTA and ethics oversight
Nothing in a research-grade supply arrangement authorises use in people. Anyone planning a trial with an unapproved therapeutic good in Australia must either notify the TGA through the Clinical Trial Notification (CTN) scheme or apply through the Clinical Trial Application (CTA) scheme. The TGA's clinical trial guidance also sets out the role of a Human Research Ethics Committee. The Department of Health's research overview explains how trials fit within the wider framework.
A trial sponsor needs product evidence that supports the submission: identity, purity, stability and batch traceability. A research-grade CoA is a starting point for that file, but it does not replace manufacturing standards a sponsor may be required to meet for human use. Raise this with the TGA and your HREC early.
Prescribers and the clinical pathway
Clinical access is a different channel from research supply. The TGA publishes information for health practitioners: established pathways exist for prescribers to access unapproved goods, including some peptides, for patients under their care where clinically appropriate. Because the TGA has not evaluated these products, responsibility for safety and quality sits with the practitioner and patient.
Compounding pharmacies face advertising limits too. They may not advertise prescription-only medicines, including compounded peptides, to the public, as shown in the TGA's undertaking accepted from a compounding pharmacy over weight-loss medicine advertising. For the prescription side, see our peptide prescription requirements guide.
Supplier due diligence: what to verify
A CoA does not make a purchase lawful. It does show whether the material is what the label says. A reasonable supplier checklist:
- Identity: mass spectrometry data confirming molecular weight.
- Purity: HPLC chromatogram with the stated percentage, not a bare number.
- Traceability: batch number on vial, CoA and invoice, matching.
- Independence: testing by a third party, with the lab named.
- Claims: no dosing advice, no therapeutic or cosmetic outcome claims, no human-use instructions.
- Customer screening: the supplier asks who the buyer is and what the intended use is.
- Logistics: clear shipping, customs and returns terms.
Our walkthrough, 4 steps to verify COAs for research versus clinical peptides, details how to read these documents, and What Is a Research Grade Peptide? explains the grade itself.
An internal compliance file, step by step
- Define the use. Write the intended application in one paragraph, confined to in-vitro or non-human work.
- Check status. For each compound, record the Poisons Standard entry, ARTG status and import requirements, with the date checked.
- Qualify the supplier. File CoA, test method, batch number and testing laboratory.
- Record receipt. Log batch, quantity, storage and who holds it.
- Track use. Keep quantities used and disposal.
- Escalate human use. Any proposal involving people goes to your HREC and, for a trial, through CTN or CTA before anything else happens.
Review the file when schedules or TGA guidance change. The TGA's peptide products hub is the page to monitor; it was last updated on 23 September 2026.
Our perspective
Compliance starts with refusing to blur categories. We supply research-grade peptides for laboratory work, and we treat the documentation as part of the product.
- Each compound in the catalogue is independently tested, with HPLC verification to ≥99% purity.
- Batch documentation is traceable, and a Certificate of Analysis is available on request.
- Material is intended for qualified researchers and institutions. It is not for human use, and a label does not change that or the buyer's legal duties.
- Buyers carry responsibility for scheduling, import and ethics checks. We encourage them to complete these before ordering.
Given the TGA's position on labelling, we think the credible response from a supplier is evidence: data a buyer can verify, and no claims a buyer cannot support.
— Tintastic
Ordering for laboratory use
The Peptastic Labs catalogue lists research-grade compounds across Metabolic, Cognitive & Neuro, Tissue & Repair, Longevity, Cosmetic Science, Hormone & Reproductive, Blends and Ancillaries & Reagents. Request the CoA for the batch before you order, and file it with your compliance records. Bulk and wholesale options are available for institutions.
FAQ
Is a "research use only" label enough to make a peptide sale compliant?
No. The TGA says such wording does not change a product's regulatory status. If a product is marketed or used to modify physiological processes, it is treated as a therapeutic good regardless of the label.
Can a laboratory import research peptides into Australia?
Possibly, but each compound must be checked against the Poisons Standard and TGA import requirements, and the Australian Border Force can intercept and seize unlawful imports. Keep paperwork for every shipment, and confirm the position for a specific peptide with the TGA before ordering.
What approvals do I need to use an unapproved peptide in a human trial?
You must notify the TGA under the CTN scheme or apply under the CTA scheme, and have oversight from a Human Research Ethics Committee. A supplier's research-grade CoA does not substitute for either step.
What documents should I ask a peptide supplier for?
Ask for a batch-specific CoA with HPLC purity and mass spec identity data, the name of the testing laboratory, and a batch number that matches the vial and invoice. Be cautious of a supplier that makes therapeutic claims or gives dosing advice.
Sources
- How we regulate therapeutic peptide products (TGA)
- Peptide products (TGA)
- Concerns regarding the public health risks associated with unapproved peptide products (Department of Health, Disability and Ageing)
- Market authorisation for regulation (Department of Health, Disability and Ageing)
- Counterfeit semaglutide vials (TGA)
- Medical Product Alert N°2/2024: Falsified Ozempic (WHO))
- Notice of interim decisions on the Poisons Standard (TGA)
- How we regulate Australian clinical trials that use unapproved therapeutic goods (TGA)
- About health and medical research in Australia (Department of Health, Disability and Ageing)
- Peptide product information for health practitioners (TGA)
- Compounding pharmacy advertising undertaking (TGA)